Material and Methods
Retrospective data analysisThe study population consisted of all consecutive cases of RhD negative
pregnant women with request from the delivery ward for type-and-screen
test, between October 2010 and October 2012 in the Stockholm region,
Sweden. After this period, an RhD-negative test panel for
type-and-screen requests in RhD negative women was introduced, in order
not to cause delay when blood transfusions were needed. In the
laboratory information system, the proportion of RhD negative women,
with an RHD positive fetus, and a negative type-and-screen test
at delivery was identified retrospectively, i.e. those where the anti-D
prophylaxis administered in gestational week 28, at that time
RhesonativĀ®, 1250 IU, (Octapharma, AG, Austria) was not detectable at
delivery.